Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Cryoablation, Rilafup α, and Chemotherapy for iCCA and GBC
NCT07726446Phase 2Recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in intrahepatic cholangiocarcinoma (ICC) and gallbladder cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Oct 2026; status: recruiting.
02
Conditions
intrahepatic cholangiocarcinoma (ICC)gallbladder cancer
Beyond the preview
Go deeper on NCT07726446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07726446.